Premium
Vitiligo‐like lesions and immune checkpoint inhibition therapy: is it truly an adverse event exclusive to patients with melanoma?
Author(s) -
RodríguezLomba E.,
MolinaLópez I.,
SuárezFernández R.,
BaniandrésRodríguez O.
Publication year - 2018
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/ced.13382
Subject(s) - vitiligo , medicine , adverse effect , melanoma , dermatology , immune system , nivolumab , immunology , oncology , immunotherapy , cancer research